NCT04710199View on ClinicalTrials.gov

Trial to Evaluate the Safety and Efficacy of Maraviroc in Patients Hospitalized for Coronavirus Disease 2019 (COVID-19)

PHASE2CompletedINTERVENTIONAL
Enrollment

44

Participants

Timeline

Start Date

February 23, 2021

Primary Completion Date

July 8, 2021

Study Completion Date

July 8, 2021

Conditions
Virus Diseases
Interventions
DRUG

Maraviroc experimental group

300-milligram dose of the drug two times daily , oral way. During 14 days.

OTHER

Standard treatment

It is based on the treatment protocol for hospitalized COVID-19 patients and that will depend on the clinical status of the patient.

Trial Locations (2)

41013

Hospital Universitario Virgen del Rocio, Seville

Hospital Universitario Virgen del Rocío, Seville

All Listed Sponsors
lead

Fundación Pública Andaluza para la gestión de la Investigación en Sevilla

OTHER

NCT04710199 - Trial to Evaluate the Safety and Efficacy of Maraviroc in Patients Hospitalized for Coronavirus Disease 2019 (COVID-19) | Biotech Hunter | Biotech Hunter